Cimetidine (SKF-92334) hydrochloride is an orally active and inversehistamine H2 receptorantagonist with aK_iof 0.6 μM. Cimetidine hydrochloride is a gastric acid reducer, and can be used for duodenal and gastric ulcers research. Cimetidine hydrochloride has anti-cancer and anti-inflammatory activity^[1][2][5].

Cimetidine (SKF-92334) hydrochloride, a partial agonist for H2R, has a pharmacological profile different from ranitidine and famotidine, possibly contributing to its antitumor activity on gastrointestinal cancers [1]. Cimetidine hydrochloride has no effect on the uptake and cytotoxicity of cisplatin in ovarian cancer cells with high OCT2 mRNA levels (IGROV-1 cells)^[3].
Cimetidine hydrochloride shows no effect on proliferation, survival, migration and invasion of 3LL cells. Cimetidine hydrochloride reverses MDSC-mediated T-cell suppression, and improves IFN-γ production^[4].
Cimetidine-mediated down-regulation of NCAM involved suppression of the nuclear translocation of NF-kappaB, a transcriptional activator of NCAM gene expression^[5].

Cimetidine (SKF-92334) hydrochloride reduces CD11b(+)Gr-1(+) myeloid derived-suppressive cell (MDSC) accumulation in spleen, blood and tumor tissue of tumor-bearing mice^[4].
Cimetidine hydrochloride exerts a beneficial effect on periodontal disease in rats, decreasing the RANKL/OPG ratio in gingival connective tissue and reducing alveolar bone resorption^[6].

288.80

C₁₀H₁₇ClN₆S

70059-30-2

盐酸西咪替丁；盐酸甲氰咪胍；盐酸甲氰咪胺

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.